GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (tesaglitazar) in Subjects with Type 2 Diabetes

Study identifier:SH-SBD-0001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Dose-Finding, Efficacy, and Safety of AZ 242 (tesaglitazar) in Subjects with Type 2 Diabetes

Medical condition

Type 2 Diabetes

Phase

Phase 2

Healthy volunteers

No

Study drug

Tesaglitazar, Pioglitazone

Sex

All

Actual Enrollment

500

Study type

Interventional

Age

30 Years - 50 Years

Date

Study Start Date: 01 Apr 2002
Primary Completion Date: -
Estimated Study Completion Date: 01 Jun 2003

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria